Beneficial effects of Rosuvastatin alone and in combination with extended-release Niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels

American Journal of Cardiology

Volumn 91, Issue 11, 2003, Pages 1304-1310

  Capuzzi, David M ^a   Morgan, John M ^b   Weiss, Robert J ^b   Chitra, Rohini R ^b   Hutchinson, Howard G ^b   Cressman, Michael D ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; FLUSHING; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PAIN; PARESTHESIA; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VASODILATATION;

EID: 0037846468     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00318-7     Document Type: Article

References (28)

1. Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effects of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 88:2001;504-508.
2. Davidson M.H., Ma P.T.S., Stein E., Gotto A.M. Jr, Raza A., Chitra R., Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 89:2002;268-275.
3. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients a randomized double-blind study . J Cardiovasc Risk. 8:2001;383-390.
4. Olsson A.G., Istad H., Luurila O., Ose L., Stender S., Tuomilehto J., Wiklund O., Southworth H., Pears J., Wilpshaar J.W. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 144:2002;1044-1051.
5. Brown W.V., Bays H.E., Hassman D.R., McKenney J., Chitra R., Hutchinson H., Miller E. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia a randomized, double-blind, 52-week trial . Am Heart J. 144:2002;1036-1043.
6. Knopp R.H., Ginsberg J., Albers J.J., Hoff C., Ogilvie J.T., Warnick G.R., Burrows E., Retzlaff B., Poole M. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects clues to mechanism of action of niacin . Metabolism. 34:1985;642-650.
7. Morgan J.M., Capuzzi D.M., Guyton J.R., Centor R.M., Goldberg R., Robbins D.C., DiPette D., Jenkins S., Marcovina S. Treatment effects of niaspan, a controlled-release niacin, in patients with hypercholesterolemia a placebo-controlled trial . J Cardiovasc Pharmacol Ther. 1:1996;195-202.
8. Capuzzi D.M., Guyton J.R., Morgan J.M., Goldberg A.C., Kreisberg R.A., Brusco O.A., Brody J. Efficacy and safety of an extended-release niacin (niaspan) a long-term study . Am J Cardiol. 82:(suppl):1998;74U-81U.
9. Knopp R.H., Alagona P., Davidson M., Goldberg A.C., Kafonek S.D., Kashyap M., Sprecher D., Superko H.R., Jenkins S., Marcovina S. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 47:1998;1097-1104.
10. Goldberg A., Alagona P. Jr, Capuzzi D.M., Guyton J., Morgan J.M., Rodgers J., Sachson R., Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 85:2000;1100-1105.
11. Peters J.R., Quiter E.S., Brekke M.L., Admire J., Brekke M.J., Mullis R.M., Hunninghake D.B. The eating pattern assessment tool a simple instrument for assessing dietary fat and cholesterol intake . J Am Diet Assoc. 94:1994;1008-1013.
12. Summary of the Second Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
13. Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung, and Blood Institute lipid standardization program an approach to accurate and precise lipid measurements . Clin Lab Med. 9:1989;105-135.
14. Hainline A Jr, Karon J, Lippel K, eds. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis. 2nd Ed. Bethesda, MD: National Heart, Lung, and Blood Institute, NIH Publication 75-628 (revised), 1982.
15. Steiner P.M., Freidel J., Bremmer W.F., Stein E.A. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Research Clinics' methodology. (abstr) J Clin Chem Clin Biochem. 19:1981;850.
16. Marcovina S.M., Adolphson J.L., Parlavecchia M., Albers J.J. Effects of lyophilization of serum on the measurement of apolipoproteins A-I and B. Clin Chem. 36:1990;366-369.
17. Marcovina S.M., Albers J.J., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurement of apolipoproteins A-I and B III: comparability of apolipoprotein A-I values by use of international reference material . Clin Chem. 39:1993;773-781.
18. Vu Dac N., Mezdour H., Parra H.J., Luc G., Luyeye I., Fruchart J.C. A selective bi-site immunoenzymatic procedure for human Lp(a) lipoprotein quantification using monoclonal antibodies against apo[a] and apoB. J Lipid Res. 30:1989;1437-1443.
19. Montgomery D.C. Design, and Analysis of Experiments. 2nd Ed:1984;John Wiley & Sons, New York, NY.
20. Capuzzi D.M., Morgan J.M., Brusco O.A., Intenzo C.M. Niacin dosing relationship to benefits and adverse effects . Curr Atheroscler Rep. 2:2000;64-71.
21. Knopp R.H. Evaluating niacin in its various forms. Am J Cardiol. 86:(suppl):2000;51L-56L.
22. Brown B.G., Zhao X.-Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 345:2001;1583-1592.
23. Kashyap M.L., McGovern M.E., Berra K., Guyton J.R., Kwiterovich P.O., Harper W.L., Toth P.D., Favrot L.K., Kerzner B., Nash S.D., Bays H.E., Simmons P.D. Long term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 89:2002;672-678.
24. Van J.T., Pan J., Wasty T., Chan E., Wu X., Charles M.A. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus. Am J Cardiol. 89:2002;1306-1308.
25. Grundy S.M., Vega G.L., McGovern M.E., Tulloch B.R., Kendall D.M., Fitz-Patrick D., Ganda O.P., Rosenson R.S., Buse J.B., Robertson D.D., Sheehan J.P. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial . Arch Intern Med. 162:2002;1568-1576.
26. Guyton J.R., Blazing M.A., Hagar J., Kashyap M.L., Knopp R.H., McKenney J.M., Nash D.T., Nash S.D. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 160:2000;1177-1184.
27. Pan J., Van J.T., Chan E., Kesala R.L., Lin M., Charles M.A. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism. 51:2002;1120-1127.
28. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.